Botulinum toxin type A reduces the expression of transient receptor potential melastatin 3 and transient receptor potential vanilloid type 4 in the trigeminal subnucleus caudalis of a rat model of trigeminal neuralgia
Authors:
- Qiuyang SuQSQiuyang Su
- Yajun LianYLYajun Lian
- Yuan ChenYCYuan Chen
- 3 July 2019
- journal article
- research article
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 30 (10) , 735-740
Abstract
This study was designed to investigate the expression of transient receptor potential melastatin 3 (TRPM3) and transient receptor potential vanilloid type 4 (TRPV4) in the trigeminal spinal subnucleus caudalis of a rat model of trigeminal neuralgia (TN). The influence of botulinum toxin type A (BTX-A) on the expression of these channels was also explored. In this study, a model was established involving chronic constriction injury to the infraorbital nerve (ION-CCI), inducing TN. To explore the effects of BTX-A and whether it was dose related, rats were divided randomly into four groups: a control group, an ION-CCI group, a 3 U group, and a 10 U group (which received 3 and 10 U/kg BTX-A injections, respectively). Von Frey hairs were used to determine the pain threshold of the rats. The expression of TRPM3 and TRPV4 in the trigeminal spinal subnucleus caudalis was detected using western blots and immunohistochemistry. The pain thresholds of rats decreased to a minimum 14 days after ION-CCI. Compared with the ION-CCI group, the pain thresholds of the 3 and 10 U groups were significantly higher 4 days after the subcutaneous injection of BTX-A (P<0.05). The expression of TRPM3 and TRPV4 in the ION-CCI group was significantly higher than that in the control group (P<0.05). TRPM3 and TRPV4 expression in the 3 and 10 U groups was significantly lower than that in the ION-CCI group (P<0.05). In conclusion, overexpression of TRPM3 and TRPV4 can jointly mediate the occurrence of mechanical hyperalgesia in TN. The analgesic effects of BTX-A may be related to the inhibition of TRPM3 and TRPV4 expression.Keywords
This publication has 19 references indexed in Scilit:
- Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trialThe Journal of Headache and Pain, 2014
- Puerarin Protects Hippocampal Neurons Against Cell Death in Pilocarpine-Induced Seizures Through Antioxidant and Anti-Apoptotic MechanismsCellular and Molecular Neurobiology, 2014
- Trafficking of ThermoTRP ChannelsMembranes, 2014
- Molecular Mechanism of TRP Channels2013
- Botulinum toxin’s axonal transport from periphery to the spinal cordNeurochemistry International, 2012
- TRPM3 Is a Nociceptor Channel Involved in the Detection of Noxious HeatNeuron, 2011
- Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat modelsEuropean Journal of Pharmacology, 2009
- Mechanisms operated by endothelin ETA and ETB receptors in the trigeminal ganglion contribute to orofacial thermal hyperalgesia induced by infraorbital nerve constriction in ratsNeuropeptides, 2009
- A transient receptor potential vanilloid 4 contributes to mechanical allodynia following chronic compression of dorsal root ganglion in ratsNeuroscience Letters, 2008
- P2X3 Receptor Mediates Heat Hyperalgesia in a Rat Model of Trigeminal Neuropathic PainThe Journal of Pain, 2007